MOTOR- A Phase 2 Study of the Safety, Efficacy and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy
Project Description:
this study is a randomized placebo-controlled, multi-center study investigating the safety and efficacy of RTA 408, an activator of Nrf2 and inhibitor of NF kappaB, in patients with mitochondrial myopathy
Keyword(s):
mitochondrial myopathy
Core Function(s):
Performing Direct and/or Demonstration Services
Area of Emphasis
Quality Assurance, Health-Related Activities
Target Audience:
Family Members/Caregivers
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
Single-County
COVID-19 Related Data:
N/A